To your second point - it is entirely possible that people are traveling abroad to get medical care that was developed here but not yet approved for the general public. That doesn't contradict their original point. I think they more than just hint that the problem is regulatory. The fact that investing in medtech has a late exit time period speaks to the regulatory hurdles and they point that out in the article.